Methylphenidate in Australia: PBS Cost & Shortages (2026)

Methylphenidate is a prescription stimulant medicine used to treat ADHD. In Australia it is sold as immediate-release and modified-release products under brand names including Ritalin, Ritalin LA, Concerta and Rubifen LA, as well as generic brands.

The active ingredient may be the same, but the products are not all interchangeable. They release methylphenidate at different rates, come in different strengths and may require different dosing schedules. A pharmacist can tell you whether a prescription allows brand substitution; changes to the formulation or dose should be discussed with the prescriber.

The Australian ADHD clinical guideline recommends stimulants including methylphenidate, dexamfetamine and lisdexamfetamine as first-line medication options for most people aged 6 and over when medication is appropriate. It does not identify one stimulant as universally best: benefits, adverse effects, duration needs, other health conditions and personal circumstances all matter.

This page is factual information, not a recommendation to start, stop or change medication. For the broader treatment context, see ADHD medication in Australia and ADHD treatment options.

Ritalin and Concerta are brand names, while methylphenidate is the active ingredient. The practical difference is mainly the release formulation, not whether one label is inherently stronger or better.

The PBS lists multiple strengths and brands in each category. The release mechanism affects how quickly the medicine becomes available and how long it acts, so the milligram number alone does not make two products equivalent. Do not split, crush or open a modified-release product unless its Consumer Medicine Information or a pharmacist specifically says that is permitted.

If a pharmacy cannot supply the exact product on a prescription, ask the pharmacist whether an equivalent brand can legally and clinically be substituted. A different release type generally requires the prescriber to issue or amend the prescription.

PBS-listed methylphenidate products are authority required. That means the prescriber must confirm that the relevant PBS criteria are met when issuing a subsidised prescription.

These are maximum co-payments, not a guaranteed shelf price for every product. A brand premium or other charge may apply in some circumstances, and a private prescription can cost more. Ask the pharmacy for the exact price before dispensing if cost affects your choice.

Eligible PBS spending counts toward the annual PBS Safety Net. Our PBS guide for ADHD medication explains authority prescriptions, co-payments, brand premiums and Safety Net thresholds in more detail.

Most of the major methylphenidate supply disruptions have resolved, but the position still differs by product. In its update of 30 June 2026, the TGA reported:

A resolved national shortage does not guarantee that every pharmacy has every strength in stock. If your usual product is unavailable:

• Ask the pharmacist to check wholesalers and nearby pharmacies.
• Ask whether an equivalent brand can be substituted on the existing prescription.
• Contact the prescriber if a different release formulation or strength is needed.
• Do not change the dose, combine products or ration medication without clinical advice.

Supply information can change quickly. Check the TGA's current shortage reports rather than relying on an older article or social-media post. Our ADHD medication shortage guide covers the practical steps in more detail.

Methylphenidate is a Schedule 8 controlled medicine, so prescribing is governed by both state or territory rules and PBS requirements.

Psychiatrists and paediatricians can initiate treatment across Australia. Whether a GP can initiate methylphenidate, continue a specialist's prescription or needs a permit depends on the jurisdiction and the patient's circumstances. Queensland and South Australia have introduced broader trained-GP pathways, while other states use continuation, co-management or permit models.

These rules are changing during 2026. See the current state-by-state guide to GP ADHD diagnosis and prescribing rather than assuming that a rule in one state applies nationally.

Methylphenidate and amphetamine-based medicines such as lisdexamfetamine (Vyvanse) and dexamfetamine are different stimulant classes. Australian guidelines include both classes as first-line options when stimulant treatment is appropriate and report minimal overall differences in efficacy and tolerability at the population level.

That does not mean they feel the same to an individual. Response, adverse effects, how long coverage is needed, other medicines and health conditions can all affect the prescriber's choice. A poor response to one formulation does not establish what will happen with every medicine in that class.

There is no safe universal conversion that a patient should apply themselves. Switching class or release formulation requires a new clinical plan and may require a new prescription. For factual information about the other long-acting class, see the Vyvanse guide.

Methylphenidate can cause adverse effects and is not suitable for everyone. The exact warnings vary by product and formulation, so read the Consumer Medicine Information supplied with your medicine and discuss monitoring with the prescriber.

The TGA changed methylphenidate's Australian pregnancy category to Category D after reviewing safety data. Category D does not mean the medicine must always be stopped; it means there is evidence of risk that must be weighed against the benefits in the individual's circumstances. If you are pregnant, planning pregnancy or breastfeeding, talk to the prescriber promptly rather than stopping treatment without advice.

Contact a healthcare professional if adverse effects are persistent, severe or concerning. Seek urgent medical help for chest pain, severe shortness of breath, fainting, severe agitation or other acute symptoms. In an emergency, call 000.